** Shares of drugmaker MannKind rise 2.1% to $6.81 premarket
** MNKD and partner Cipla say the Central Drugs Standard Control Organisation (CDSCO) in India has approved MNKD's insulin inhalation powder Afrezza
** India has the second highest burden of diabetes worldwide the companies say
** MNKD expects to ship product for CIPL by end of 2025
** Under the agreement, CIPL is responsible for obtaining regulatory approvals to distribute Afrezza in India as well as marketing and sales activities, while MNKD is responsible for supplying it
** Up to last close, MNKD up 83.2% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.